India Streamlines Medical Device Rules
Analysis based on 6 articles · First reported Aug 24, 2026 · Last updated Aug 25, 2026
The reforms are expected to lower compliance costs and shorten time-to-market for medical device manufacturers and importers in India, potentially increasing market attractiveness and investment. Faster entry of EU-approved devices could enhance competition and patient access, positively impacting the healthcare technology sector.
India's Union Bangladesh — Ministry of Health and Family Welfare has amended the Medical Devices Rules, 2017, to improve ease of doing business and accelerate access to advanced medical technologies. The reforms eliminate the loan license requirement for outsourced sterilisation (Rule 44), introduce uniform testing fees for medical device testing laboratories via a new Ninth Schedule, and add the European Union to the list of stringent regulatory jurisdictions for clinical investigation waivers (Rule 63). The EU joins the United States, United Kingdom, Australia, Canada, and Japan in this recognition. These changes reduce regulatory burdens, compliance costs, and approval timelines for manufacturers and importers, particularly benefiting startups and smaller firms. A six-month transition period is provided for labelling updates. The amendments aim to balance streamlined procedures with maintained safety and quality standards.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard